The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors

Author： Filippatos Theodosios D Athyros Vasilios G Elisaf Moses S

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.10, Iss.6, 2014-06, pp. : 787-812

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Pharmacokinetic Factors in the Adverse Cardiovascular Effects of Antipsychotic Drugs

By Brown C.S.

Clinical Pharmacokinetics, Vol. 43, Iss. 1, 2004-01 ,pp. : 33-56

Adis International

Access to resources Recommend Favorite

Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations

By Scheen André J

Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, Iss. 5, 2014-05 ,pp. : 647-663

Informa Healthcare

Access to resources Recommend Favorite

Computational Development of Selective nNOS Inhibitors: Binding Modes and Pharmacokinetic Considerations

Current Medicinal Chemistry, Vol. 22, Iss. 21, 2015-01 ,pp. : 2558-2579

Bentham Science Publishers

Access to resources Recommend Favorite

Keratoconus and crosslinking: pharmacokinetic considerations

By Chan Clara C Squissato Victoria

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 12, 2013-12 ,pp. : 1613-1624

Informa Healthcare

Access to resources Recommend Favorite

Cholinergic Adverse Effects of Cholinesterase Inhibitors in Alzheimer's Disease: Epidemiology and Management

By Gauthier S.

Drugs & Aging, Vol. 18, Iss. 11, 2001-01 ,pp. : 853-862

Adis International

Access to resources Recommend Favorite